NewAmsterdam Pharma Co N.V. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
NewAmsterdam announced a positive Committee for Medicinal Products for Human Use (CHMP) opinion in July 2026 recommending marketing authorization for obicetrapib 10 mg monotherapy and obicetrapib 10 mg plus ezetimibe 10 mg fixed-dose combination for primary hypercholesterolemia and mixed dyslipidemia in Europe, with final European Commission decision expected later in 2026. The company plans a PREVAIL cardiovascular outcomes trial interim analysis in Q4 2026 with results expected in Q1 2027 (trial enrolled 9,500+ patients in April 2024). Cash position stood at $678.3 million as of June 30, 2026 (down from $728.9 million Dec 31, 2025); Q2 2026 net loss was $64.1 million on R&D expenses of $41.7 million and SG&A of $26.9 million.
Why this rating
CHMP approval is major regulatory milestone (~5% of market cap risk removed); PREVAIL interim readout critical to cardiovascular outcome validation. Cash burn manageable but accelerating; runway approximately 2.5 years at current rate.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.